Novartis/Amgen’s migraine drug excites with phase 3 data
Erenumab under review in US and EU
X
Novartis/Amgen’s migraine drug excites with phase 3 data
https://pharmaphorum.com/news/novartisamgen/
Teva
New Teva CEO axes R&D chief Hayden in boardroom shakeup
R&D chief Michael Hayden to leave at year end.
Huntington’s Disease wearable gets backing from NIH
BioSensics’ HDWear provides real-time motor function scores in Huntington’s patients.
Teva appoints Lundbeck’s Kare Schultz as CEO
Unlike AZ’s Soriot, Schultz “couldn’t refuse” top job at Teva.
Bidders lining up for Teva women’s health unit
Allergan generics buyout left Teva with $35m debts
AZ CEO set to take charge at Teva – report
Report raises concerns about outcome of MYSTIC trial.
Teva files orphan blockbuster hope in tardive dyskinesia
SD-809 will be vital for Teva if approved.
Orphan drugs will fuel pharma’s future – and a pricing pushback too
Evaluate predicts sales could approach $8bn if approved.
Mylan settles narcolepsy drug pay-for-delay case
Payment ends decade of litigation.